We certainly can't complain about the methodical approach...

We certainly can't complain about the methodical approach adopted by our team in each and every aspect. SYC always seems to be, not just one, but many moves ahead in the game... pre-empting and acting upon both internal and external factors that determine our future position within the industry and market.

My only complaint right now is the damage that looming option-expiry has caused to the SP. SYC would have been fully aware of the ramifications of such a low strike rate coupled with a long-dated expiry when they were issued. It would be interesting to know if a biotech fund or two are in the wings right now awaiting the latest PTX100 readout. Current volumes don't suggest accumulation on their part yet. The next few weeks are going to be interesting given the reality of our MCap now. If the data strongly indicates that we are in with a good chance for accelerated approval and that PTX100 could be on its way to become a commercial drug in a few years time, it will de-risk the company further to a level attractive to prospective VCs. Also, it may start to open those other doors as a combination drug candidate. It makes sense to get the progress as a monotherapy bedded down in the next stage (if deemed successful) before pursuing combination trials.

Yeah, ODD we have and if we secure approval for a pivotal trial... as Steve says: "It will be huuuuuge... huge, huge, huge!" Safe to say we can kiss 8 and 9c goodbye foreva! (with two more exclamation marks). Still a wait to go but shaping up noicely!